Shalby

Why is Shalby Ltd. falling/rising?

As of 22-Jun, Shalby Ltd.'s stock price is rising to 175.25, up 2.61%, due to strong financial performance, including a 125.25% increase in profit before tax and a favorable PEG ratio of 0.1, despite a year-to-date decline. The stock's recent upward trend follows a reversal after previous declines, although investor participation has decreased.

As of 22-Jun, Shalby Ltd.'s stock price is rising, currently at 175.25, reflecting a change of 4.45 or 2.61% increase. This upward movement can be attributed to several factors. Notably, the stock has outperformed its sector by 1.12% today and has experienced a trend reversal after two consecutive days of decline. Additionally, the stock reached an intraday high of Rs 176, marking a 3.04% increase during the trading session.<BR><BR>The company's financial performance also supports this rise. In the latest results, the profit before tax (PBT) has significantly grown by 125.25% to Rs 1.53 crore, and the profit after tax (PAT) for the last six months is reported at Rs 20.09 crore, indicating strong earnings growth. Furthermore, the earnings per share (EPS) for the quarter is at its highest level of Rs 1.70. <BR><BR>Despite a year-to-date decline of 13.82%, the stock's profits have increased dramatically by 501.3% over the past year, which, combined with a low PEG ratio of 0.1, suggests that the stock is undervalued compared to its peers. The company's debt to equity ratio is also favorable at 0.24 times, contributing to a solid financial foundation.<BR><BR>However, it is important to note that there has been a decline in investor participation, with delivery volume falling by 32.18% against the five-day average. Despite this, the overall positive financial indicators and the recent performance improvements are driving the stock's rise.

Which are the latest news on Shalby?

What does Shalby do?

Shalby Ltd. is a small-cap hospital company based in India, originally incorporated in 2004, with recent quarterly net sales of 287 Cr and net profit of 18 Cr as of March 2026. The company operates with a market cap of INR 1,844 Cr and key financial metrics include a P/E ratio of 48.00 and a debt-equity ratio of 0.51.

Overview: <BR>Shalby Ltd. operates in the hospital industry and is categorized as a small-cap company.<BR><BR>History: <BR>Shalby Ltd. was originally incorporated as 'Shalby Hospital Private Limited' in 2004. It transitioned to a public limited company in 2006, changing its name to 'Shalby Hospital Public Limited,' and later to 'Shalby Hospitals Limited' and finally to 'Shalby Limited' in 2008. The most recent quarterly results reported net sales and net profit for March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 287 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 18 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 1,844 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 48.00 <BR>Industry P/E: 60 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.51 <BR>Return on Equity: 3.72% <BR>Price to Book: 1.82 <BR><BR>Contact Details: <BR>Address: Opp Karnawati Club, Sarkhej Gandhinagar Highway Ahmedabad Gujarat : 380015 <BR>Tel: 91-79-40203000 <BR>Email: companysecretary@shalby.in <BR>Website: http://www.shalby.org

How big is Shalby?

As of 10th June, Shalby Ltd. has a market capitalization of 1,844.00 Cr, with recent net sales of 1,141.44 Cr and a net profit of 37.40 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Shalby Ltd. has a market capitalization of 1,844.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 1,141.44 Cr, while the sum of Net Profit for the same period is 37.40 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds stand at 992.19 Cr, and Total Assets are valued at 1,703.65 Cr.

Who are in the management team of Shalby?

The management team of Shalby includes Vikram Shah (Chairman & Managing Director), Sushobhan Dasgupta (Vice Chairman), and Tushar Shah (Company Secretary & Compliance Officer), along with several Independent Directors such as Shyamal S Joshi and Umesh Menon. This diverse team brings a wide range of expertise to the company.

The management team of Shalby includes the following individuals:<BR><BR>1. **Vikram Shah** - Chairman & Managing Director<BR>2. **Sushobhan Dasgupta** - Vice Chairman<BR>3. **Tushar Shah** - Company Secretary & Compliance Officer<BR><BR>Additionally, the Board of Directors features several Independent Directors:<BR>- **Shyamal S Joshi**<BR>- **Umesh Menon**<BR>- **Ashok Bhatia**<BR>- **Tej Malhotra**<BR>- **Sujana Shah**<BR>- **Vijay Kishanlal Kedia**<BR><BR>This team brings a diverse range of expertise to the company. If you need more specific information about any of the members or their roles, feel free to ask!

Who are the peers of the Shalby?

Shalby's peers include Kovai Medical, Artemis Medicare, Indrapr.Medical, Dr Agarwal's Eye, KMC Speciality, GPT Healthcare, Asarfi Hospital, Unihealth Hosp, and Chandan Healthca. KMC Speciality leads in 1-year returns at 75.24%, while Shalby has a return of -10.87%.

Peers: The peers of Shalby are Kovai Medical, Artemis Medicare, Indrapr.Medical, Dr Agarwal's Eye, KMC Speciality, GPT Healthcare, Asarfi Hospital, Unihealth Hosp, and Chandan Healthca.<BR><BR>Quality Snapshot: Excellent management risk is observed at GPT Healthcare, while Good management risk is found at Kovai Medical and KMC Speciality, and the rest have Average management risk. Growth is Excellent at Artemis Medicare, Dr Agarwal's Eye, Unihealth Hosp, and Chandan Healthca, while Good growth is noted at Indrapr.Medical, KMC Speciality, and Asarfi Hospital, and the rest have Below Average or Average growth. Capital Structure is Excellent at Indrapr.Medical and KMC Speciality, Good at Kovai Medical, Shalby, Asarfi Hospital, and Chandan Healthca, while the rest have Average or Below Average capital structure.<BR><BR>Return Snapshot: KMC Speciality has the highest 1-year return at 75.24%, while Indrapr.Medical has the lowest at -8.75%, with Shalby's 1-year return of -10.87% being lower than both. Additionally, the six-month return is negative for Shalby, Indrapr.Medical, Artemis Medicare, and GPT Healthcare.

Should I buy, sell or hold Shalby Ltd.?

When is the next results date for Shalby Ltd.?

The next results date for Shalby Ltd. is 27 May 2026.

The next results date for Shalby Ltd. is scheduled for 27 May 2026.

Are Shalby Ltd. latest results good or bad?

Shalby Ltd.'s latest Q3 FY26 results are concerning, showing a 78.90% decline in net profit and a 4.66% drop in revenue, marking two consecutive quarters of revenue decline. The company's performance is significantly below industry standards, indicating serious operational challenges and poor financial health.

Shalby Ltd.'s latest results for Q3 FY26 indicate a concerning performance. The company reported a net profit of ₹1.77 crore, which represents a dramatic decline of 78.90% quarter-on-quarter. Revenue also decreased by 4.66% to ₹272.13 crore, marking the second consecutive quarter of revenue decline. <BR><BR>The operating margin, excluding other income, fell significantly to 11.12% from 14.58% in the previous quarter, reflecting rising cost pressures and operational inefficiencies. Additionally, the profit before tax was just ₹9.23 crore, down from ₹19.07 crore in Q2 FY26, and an unusually high tax rate of 86.13% severely impacted net profitability.<BR><BR>In the context of the broader hospital sector, which has been experiencing robust growth, Shalby's underperformance stands out. The stock has also significantly lagged behind its peers, with a return of negative 17.25% over the past year compared to the hospital sector's positive 25.33% return.<BR><BR>Overall, the results reflect serious operational challenges and a deterioration in financial health, suggesting that the latest performance is indeed bad for Shalby Ltd.

Is Shalby technically bullish or bearish?

As of December 1, 2025, the market trend has shifted to mildly bearish, supported by bearish MACD readings, Bollinger Bands, and Dow Theory, despite some daily moving averages indicating mild bullishness.

As of 1 December 2025, the technical trend has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by weekly and monthly MACD readings indicating bearish momentum, along with Bollinger Bands and KST both signaling bearish conditions. The Dow Theory also supports a mildly bearish outlook on both weekly and monthly time frames. Although daily moving averages show a mildly bullish signal, the overall technical indicators suggest a bearish sentiment prevailing in the market.

How has been the historical performance of Shalby?

Shalby's historical performance shows strong revenue growth, with net sales increasing to 1,086.96 Cr by Mar'25, but rising expenditures led to a decline in operating profit and profit after tax, which fell to 1.92 Cr. Additionally, cash flow from operating activities turned negative in Mar'25, indicating potential liquidity issues.

Answer:<BR>The historical performance of Shalby shows significant growth in net sales and operating income over the years, with net sales increasing from 430.90 Cr in Mar'21 to 1,086.96 Cr in Mar'25. Total operating income followed a similar trend, reaching 1,086.96 Cr in Mar'25, up from 804.92 Cr in Mar'23. However, total expenditure also rose, climbing from 344.48 Cr in Mar'21 to 954.35 Cr in Mar'25, which impacted the operating profit, which decreased from 177.04 Cr in Mar'24 to 132.61 Cr in Mar'25. Profit before tax saw a decline from 128.19 Cr in Mar'24 to 55.73 Cr in Mar'25, leading to a profit after tax of only 1.92 Cr in Mar'25 compared to 83.50 Cr in Mar'24. The earnings per share dropped significantly from 7.83 in Mar'24 to 0.58 in Mar'25. On the balance sheet, total assets increased from 1,193.54 Cr in Mar'22 to 1,703.65 Cr in Mar'25, while total liabilities also rose from 1,193.54 Cr to 1,703.65 Cr in the same period. Cash flow from operating activities turned negative in Mar'25 at -4.00 Cr, contrasting with positive cash flows in previous years.<BR><BR>Breakdown:<BR>Shalby's financial performance has shown a robust increase in net sales, which rose from 430.90 Cr in Mar'21 to 1,086.96 Cr in Mar'25, indicating strong revenue growth. Total operating income mirrored this growth, reaching 1,086.96 Cr in Mar'25. However, total expenditure surged to 954.35 Cr in Mar'25, leading to a decline in operating profit from 177.04 Cr in Mar'24 to 132.61 Cr in Mar'25. This decline was further reflected in profit before tax, which fell from 128.19 Cr in Mar'24 to 55.73 Cr in Mar'25, resulting in a profit after tax of just 1.92 Cr in Mar'25. The earnings per share also saw a drastic drop from 7.83 in Mar'24 to 0.58 in Mar'25. On the balance sheet, total assets increased significantly to 1,703.65 Cr in Mar'25, while total liabilities rose correspondingly, indicating a growing debt load. Cash flow from operating activities turned negative in Mar'25, contrasting with positive cash flows in prior years, highlighting potential liquidity challenges.

Is Shalby overvalued or undervalued?

As of October 8, 2025, Shalby is considered very attractive and undervalued, with a PE ratio of -2742.37, a price-to-book value of 2.76, and strong long-term returns of 89.9% and 190.67% over three and five years, respectively, despite recent underperformance compared to peers like Apollo Hospitals and Max Healthcare.

As of 8 October 2025, the valuation grade for Shalby has moved from attractive to very attractive. The company is currently considered undervalued, particularly given its extreme PE ratio of -2742.37 and a price-to-book value of 2.76. Other notable ratios include an EV to EBITDA of 23.96 and a ROCE of 4.99%. <BR><BR>In comparison to its peers, Shalby stands out with a significantly lower PE ratio than Apollo Hospitals, which has a PE of 70.05, and Max Healthcare, which is at 92.31. Despite the negative sentiment reflected in the recent stock performance, where Shalby has underperformed the Sensex over the past week, its long-term returns over three and five years show a robust growth of 89.9% and 190.67%, respectively, reinforcing its undervaluation narrative.

Who are the top shareholders of the Shalby?

The top shareholder of Shalby is the Shah Family Trust, led by Dr. Vikram Shah, with a 34.73% stake. Other notable shareholders include 38 foreign institutional investors with 5.2% and First Water Fund, the largest public shareholder, at 1.77%.

The top shareholders of Shalby include the Shah Family Trust, represented by Dr. Vikram Shah, who holds the largest stake at 34.73%. The company is primarily owned by its promoters, with no pledged promoter holdings. Additionally, there are 38 foreign institutional investors (FIIs) who collectively hold 5.2% of the shares. The highest public shareholder is First Water Fund, with a holding of 1.77%. Individual investors account for 11.2% of the total shareholding.

Has Shalby declared dividend?

Yes, Shalby Ltd. has declared a 12% dividend, amounting to ₹1.2 per share, with an ex-date of September 19, 2024. Despite recent negative returns in the short term, long-term performance shows positive trends, particularly over the last five years.

Shalby Ltd. has declared a 12% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 12%<BR>- Amount per share: 1.2<BR>- Ex-date: 19 Sep 24<BR><BR>Dividend Yield: 0.66%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, Shalby experienced a price return of -24.69%, with no dividend return, resulting in a total return of -24.69%.<BR><BR>Over the past year, the price return was -29.77%, with a dividend return of 0.43%, leading to a total return of -29.34%.<BR><BR>In the 2-year period, the price return was 28.62%, with a dividend return of 1.50%, resulting in a total return of 30.12%.<BR><BR>For the 3-year period, Shalby had a price return of 57.96%, a dividend return of 3.50%, culminating in a total return of 61.46%.<BR><BR>In the last 4 years, the price return was 6.68%, with a dividend return of 2.54%, leading to a total return of 9.22%.<BR><BR>Finally, over the 5-year period, Shalby achieved a price return of 167.0%, a dividend return of 7.00%, resulting in a total return of 174.0%.<BR><BR>Overall, while Shalby has declared a dividend, the recent total returns indicate significant volatility, particularly in the short term, with negative returns over the last year and six months. However, the longer-term returns show a more positive trend, especially over the 5-year period.